```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSPTAKAB1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page for STN Seminar Schedule - N. America
 NEWS  2  AUG 15  CAOLD to be discontinued on December 31, 2008
 NEWS  3  OCT 07  EPFULL enhanced with full implementation of EPC2000
 NEWS  4  OCT 07  Multiple databases enhanced for more flexible patent
                  number searching
 NEWS  5  OCT 22  Current-awareness alert (SDI) setup and editing
                  enhanced
 NEWS  6  OCT 22  WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT
                  Applications
 NEWS  7  OCT 24  CHEMLIST enhanced with intermediate list of
                  pre-registered REACH substances
 NEWS  8  NOV 21  CAS patent coverage to include exemplified prophetic
                  substances identified in English-, French-, German-,
                  and Japanese-language basic patents from 2004-present
 NEWS  9  NOV 26  MARPAT enhanced with FSORT command
 NEWS 10  NOV 26  MEDLINE year-end processing temporarily halts
                  availability of new fully-indexed citations
 NEWS 11  NOV 26  CHEMSAFE now available on STN Easy
 NEWS 12  NOV 26  Two new SET commands increase convenience of STN
                  searching
 NEWS 13  DEC 01  ChemPort single article sales feature unavailable
 NEWS 14  DEC 12  GBFULL now offers single source for full-text
                  coverage of complete UK patent families

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 08:48:52 ON 16 DEC 2008
```

=> file reg
COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION
FULL ESTIMATED COST | 0.21 | 0.21

FILE 'REGISTRY' ENTERED AT 08:49:00 ON 16 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 14 DEC 2008 HIGHEST RN 1084385-33-0
DICTIONARY FILE UPDATES: 14 DEC 2008 HIGHEST RN 1084385-33-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10579825 elected.str



chain nodes :
6 13 14 15 18 20
ring nodes :
1 2 3 4 5 7 8 9 10 11 12 21 22 23 24 25 26 27 28 29 30 31 32

chain bonds :
1-6 2-13 4-7 10-18 13-14 13-20 14-15 14-24 18-27
ring bonds :
1-2 1-5 2-3 3-4 4-5 7-8 7-12 8-9 9-10 10-11 11-12 21-22 21-26 22-23
23-24 24-25 25-26 27-28 27-32 28-29 29-30 30-31 31-32

exact/norm bonds :
1-2 1-5 10-18 13-14 13-20 14-24 18-27
exact bonds :
1-6 2-3 2-13 3-4 4-5 4-7 14-15
normalized bonds :
7-8 7-12 8-9 9-10 10-11 11-12 21-22 21-26 22-23 23-24 24-25 25-26 27-28
27-32 28-29 29-30 30-31 31-32
isolated ring systems :
containing 1 : 7 : 21 : 27 :

G1:O,S,N

G2:Cb,Cy,Hy

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 18:CLASS 20:CLASS 21:Atom 22:Atom
23:Atom 24:Atom
25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:CLASS 31:CLASS 32:Atom

L1   STRUCTURE UPLOADED

=> d L1
L1 HAS NO ANSWERS
L1   STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> file caplus
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                                         ENTRY   SESSION
FULL ESTIMATED COST   0.46   0.67

FILE 'CAPLUS' ENTERED AT 08:49:17 ON 16 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 16 Dec 2008 VOL 149 ISS 25
FILE LAST UPDATED: 15 Dec 2008 (20081215/ED)

Caplus now includes complete International Patent Classification (IPC)

reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l1 SSS Full
   REGISTRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 08:49:27 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 417 TO ITERATE

100.0% PROCESSED 417 ITERATIONS 4 ANSWERS
SEARCH TIME: 00.00.01

L2 4 SEA SSS FUL L1

L3 1 L2

=> d ibib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM 1 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:469894 CAPLUS Full-text
DOCUMENT NUMBER: 143:7592
TITLE: Preparation of arylpyrrolecarboxamides as Raf kinase inhibitors for treatment of tumors.
INVENTOR(S): Finsinger, Dirk; Buchstaller, Hans-Peter; Burgdorf, Lars; Wiesner, Matthias; Amendt, Christiane; Grell, Matthias; Sirrenberg, Christian; Zenke, Frank
PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany
SOURCE: Ger. Offen., 32 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10354060	A1	20050602	DE 2003-10354060	20031119
AU 2004291255	A1	20050602	AU 2004-291255	20041026
CA 2546334	A1	20050602	CA 2004-2546334	20041026
WO 2005049603	A1	20050602	WO 2004-EP12076	20041026

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,

AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1685125	A1	20060802	EP 2004-790859	20041026
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1882571	A	20061220	CN 2004-80034345	20041026
BR 2004016690	A	20070130	BR 2004-16690	20041026
JP 2007511553	T	20070510	JP 2006-540216	20041026
IN 2006KN00936	A	20070420	IN 2006-KN936	20060417
MX 2006PA05478	A	20060811	MX 2006-PA5478	20060515
KR 2006118492	A	20061123	KR 2006-709552	20060517
US 20070149594	A1	20070628	US 2006-579825	20060517
PRIORITY APPLN. INFO.:			DE 2003-10354060 A	20031119
			WO 2004-EP12076 W	20041026

OTHER SOURCE(S): MARPAT 143:7592

GI



I

AB Title compds. [I; Ar = (substituted) Ph, naphthyl, biphenyl, heterocyclyl; X = O, S, (CH2)n, CO, (CH2)nO, (CH2)nNH, etc.; n = 1-3; Y = O, S, CHNO2, C(CN)2, NR4; R4 = H, cyano, OH, etc.; Z = Ar, ArXAr, CH2Ar, CH2ArXAr; Ar = (substituted) Ph], were prepared as Raf kinase inhibitors (no data). Thus, 4-(PhCH2O)C6H4CH2CO2H, DMF, and POCl3 were heated together at 70° for 4 h followed by cooling and addition of ice water and aqueous NaClO4 to give 98% [2-(4-benzyloxyphenyl)-3-dimethylaminoallylidene]dimethylammonium perchlorate. This was refluxed 24 h with glycine Et ester hydrochloride in EtOH containing 20% NaOEt to give 91% Et 4-(4-benzyloxyphenyl)-1H-pyrrole-2-carboxylate. Hydrogenolysis of the latter in EtOAc over Pd/C gave 91% Et 4-(4-hydroxyphenyl)-1H-pyrrole-2-carboxylate. This was heated with 4-chloropyridine-2-carboxylic acid N-methylamide at 160° for 48 h to give 40% Et 4-[4-(2-methylcarbamoylpyridin-4-yloxy)phenyl]-1H-pyrrole-2- carboxylate. Saponification with 2N NaOH in EtOH at 60° for 16 h followed by acidification with HCl gave 85% free acid, which was stirred 48 h in DMF with 5-amino-2-chlorobenzotrifluoride, N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride, and 1-hydroxybenzotriazole hydrate to give 17% 4-[4-[5-(4-chloro-3-trifluoromethylphenylcarbamoyl)-1H-pyrrol-3- yl]phenoxy]pyridine-2-carboxylic acid N-methylamide.

IT 852455-19-7P 852455-21-1P 852455-22-2P
852455-24-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of arylpyrrolecarboxamides as Raf kinase inhibitors for treatment of tumors)

RN 852455-19-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[5-[[[4-chloro-3-

(trifluoromethyl)phenyl]amino]carbonyl]-1H-pyrrol-3-yl]phenoxy]-N-methyl-
(CA INDEX NAME)



RN 852455-21-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[5-[[(3-chloro-4-methylphenyl)amino]carbonyl]-
1H-pyrrol-3-yl]phenoxy]-N-methyl- (CA INDEX NAME)



RN 852455-22-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[5-[[[2-methoxy-5-
(trifluoromethyl)phenyl]amino]carbonyl]-1H-pyrrol-3-yl]phenoxy]-N-methyl-
(CA INDEX NAME)



RN 852455-24-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[5-[[(5-chloro-2-methoxyphenyl)amino]carbonyl]-
1H-pyrrol-3-yl]phenoxy]-N-methyl- (CA INDEX NAME)




```
=> file marpat
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       6.89     186.40

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -0.80      -0.80

FILE 'MARPAT' ENTERED AT 08:51:09 ON 16 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

FILE CONTENT: 1961-PRESENT VOL 149 ISS 24 (20081212/ED)

MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US  20080280867 13 NOV 2008
DE 102008019744 30 OCT 2008
EP      1990054 12 NOV 2008
JP   2008262895 30 OCT 2008
WO   2008136863 13 NOV 2008
GB      2448808 29 OCT 2008
FR      2915685 07 NOV 2008
RU      2337918 10 NOV 2008
CA      2629177 18 OCT 2008

Expanded G-group definition display now available.

The new MARPAT User Guide is now available at:
 http://www.cas.org/support/stngen/stndoc/marpat.html.

=> s L1 SSS Full
FULL SEARCH INITIATED 08:51:13 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED -     8419 TO ITERATE

100.0% PROCESSED     8419 ITERATIONS                                3 ANSWERS
SEARCH TIME: 00.00.07
```

```
L4            3 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     125.26     311.66

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00      -0.80

FILE 'CAPLUS' ENTERED AT 08:51:25 ON 16 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 16 Dec 2008  VOL 149 ISS 25
FILE LAST UPDATED: 15 Dec 2008  (20081215/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s L4
L5            3 L4

=> d ibib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM 3 ANSWERS - CONTINUE? Y/(N):y

L5   ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2005:469894  CAPLUS  Full-text
DOCUMENT NUMBER:          143:7592
TITLE:                    Preparation of arylpyrrolecarboxamides as Raf kinase
                          inhibitors for treatment of tumors.
INVENTOR(S):              Finsinger, Dirk; Buchstaller, Hans-Peter; Burgdorf,
                          Lars; Wiesner, Matthias; Amendt, Christiane; Grell,
                          Matthias; Sirrenberg, Christian; Zenke, Frank
PATENT ASSIGNEE(S):       Merck Patent G.m.b.H., Germany
SOURCE:                   Ger. Offen., 32 pp.
                          CODEN: GWXXBX
DOCUMENT TYPE:            Patent
LANGUAGE:                 German
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:
```

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10354060	A1	20050602	DE 2003-10354060	20031119
AU 2004291255	A1	20050602	AU 2004-291255	20041026
CA 2546334	A1	20050602	CA 2004-2546334	20041026
WO 2005049603	A1	20050602	WO 2004-EP12076	20041026
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1685125	A1	20060802	EP 2004-790859	20041026
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1882571	A	20061220	CN 2004-80034345	20041026
BR 2004016690	A	20070130	BR 2004-16690	20041026
JP 2007511553	T	20070510	JP 2006-540216	20041026
IN 2006KN00936	A	20070420	IN 2006-KN936	20060417
MX 2006PA05478	A	20060811	MX 2006-PA5478	20060515
KR 2006118492	A	20061123	KR 2006-709552	20060517
US 20070149594	A1	20070628	US 2006-579825	20060517
PRIORITY APPLN. INFO.:			DE 2003-10354060 A	20031119
			WO 2004-EP12076 W	20041026

OTHER SOURCE(S): MARPAT 143:7592

GI



I

AB Title compds. [I; Ar = (substituted) Ph, naphthyl, biphenyl, heterocyclyl; X = O, S, (CH2)n, CO, (CH2)nO, (CH2)nNH, etc.; n = 1-3; Y = O, S, CHNO2, C(CN)2, NR4; R4 = H, cyano, OH, etc.; Z = Ar, ArXAr, CH2Ar, CH2ArXAr; Ar = (substituted) Ph], were prepared as Raf kinase inhibitors (no data). Thus, 4-(PhCH2O)C6H4CH2CO2H, DMF, and POCl3 were heated together at 70° for 4 h followed by cooling and addition of ice water and aqueous NaClO4 to give 98% [2-(4-benzyloxyphenyl)-3-dimethylaminoallylidene]dimethylammonium perchlorate. This was refluxed 24 h with glycine Et ester hydrochloride in EtOH containing 20% NaOEt to give 91% Et 4-(4-benzyloxyphenyl)-1H-pyrrole-2-carboxylate. Hydrogenolysis of the latter in EtOAc over Pd/C gave 91% Et 4-(4-hydroxyphenyl)-1H-pyrrole-2-carboxylate. This was heated with 4-chloropyridine-2-carboxylic acid N-methylamide at 160° for 48 h to give 40% Et 4-[4-(2-methylcarbamoylpyridin-4-yloxy)phenyl]-1H-pyrrole-2- carboxylate. Saponification with 2N NaOH in EtOH at 60° for 16 h followed by acidification with HCl gave 85% free acid, which was stirred 48 h in DMF with 5-amino-2-

chlorobenzotrifluoride, N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride, and 1-hydroxybenzotriazole hydrate to give 17% 4-[4-[5-(4-chloro-3-trifluoromethylphenylcarbamoyl)-1H-pyrrol-3- yl]phenoxy]pyridine-2-carboxylic acid N-methylamide.

L5 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:14213 CAPLUS Full-text
DOCUMENT NUMBER: 142:114071
TITLE: Preparation of substituted 5-membered ring compounds as heat shock protein 90 (HSP90) inhibitors
INVENTOR(S): Cheung, Kwai Ming; Dymock, Brian William; MacDonald, Edward; Drysdale, Martin James
PATENT ASSIGNEE(S): Vernalis Cambridge Limited, UK; Cancer Research Technology Ltd.; The Institute of Cancer Research
SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005000300	A1	20050106	WO 2004-GB2755	20040624
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1638555	A1	20060329	EP 2004-743106	20040624
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
US 20060235058	A1	20061019	US 2005-561969	20051222
PRIORITY APPLN. INFO.:			GB 2003-15111 A	20030627
			WO 2004-GB2755 W	20040624

OTHER SOURCE(S): MARPAT 142:114071
GI



I



II

AB Title compds. I [wherein A = 5-membered cycle; R1 = (un)substituted (hetero)aryl; R2 (adjacent to R1) = absence, H, carboxamide, (un)substituted (hetero)aryl, carbocycle or heterocycle; R3 (adjacent to R2) = absence, H, (un)substituted cycloalky(en)yl, alk(en/yn)yl, carboxyl, carboxamide or ester; with some limitations, or salts, N-oxides, hydrates or solvates thereof] were prepared as heat shock protein 90 (HSP90) inhibitors. Thus, 5-chloro-2,4-dimethoxyphenylamine was treated with NaNO2 in the presence of H2SO4 followed by the addition of NaN3. The resultant azide underwent cyclization with 3-(4-fluorophenyl)-3-oxopropionic acid Me ester gave intermediate II (X = OMe, R= OH). Demethylation of this compound with 48% HBr followed by esterification with EtOH yielded triazolecarboxylate II (X = OH, R = OEt), which showed IC50 <10 μM for binding to HSP90 in a fluorescence polarization assay. Therefore, I and their compns. are useful for immunosuppression or the treatment of cancers, viral disease, inflammatory diseases and so on.

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:589375 CAPLUS Full-text

DOCUMENT NUMBER: 141:140459

TITLE: Preparation of sulfamides as anti-cancer agents

INVENTOR(S): Flynn, Daniel L.; Petrillo, Peter A.

PATENT ASSIGNEE(S): Deciphera Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 168 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 9

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004060305	A2	20040722	WO 2003-US41425		20031226
WO 2004060305	A3	20050210			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 20040176395	A1	20040909	US 2003-746607		20031224
US 7279576	B2	20071009			
CA 2511840	A1	20040722	CA 2003-2511840		20031226
AU 2003303639	A1	20040729	AU 2003-303639		20031226
EP 1590344	A2	20051102	EP 2003-814980		20031226
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003017863	A	20051206	BR 2003-17863		20031226
CN 1756849	A	20060405	CN 2003-80110049		20031226
CN 1791596	A	20060621	CN 2003-80110048		20031226
JP 2006519765	T	20060831	JP 2005-508623		20031226
IN 2005CN01433	A	20070302	IN 2005-CN1433		20050628
MX 2005PA07237	A	20071115	MX 2005-PA7237		20050630
PRIORITY APPLN. INFO.:			US 2002-437304P	P	20021231
			US 2002-437403P	P	20021231

US	2002-437415P	P	20021231
US	2002-437487P	P	20021231
US	2003-463804P	P	20030418
US	2003-746545	A	20031224
US	2003-746607	A	20031224
WO	2003-US41425	W	20031226

OTHER SOURCE(S): MARPAT 141:140459

GI



I

AB Sulfamides, such as I, were prepared for use as anticancer agents which act by modulating the activation states of abl or bcr-abl α-kinase proteins. Thus, 4-HO2CC6H4CH2NHSO2NHCOR [R = pyrrolidino], prepared from 4-MeO2CC6H4CH2NH2 and pyrrolidine, was treated with the pyrimidinylaminoaniline fragment to give I, which showed 10% inhibition of non-phosphorylated abl kinase at 10μM.

=> log off
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
STN INTERNATIONAL LOGOFF AT 08:51:57 ON 16 DEC 2008